Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma

摘要: Background. In patients with hepatocellular carcinoma (hepatoma), the rate of recurrent and second primary hepatomas is high despite surgical resection percutaneous ethanol-injection therapy. We developed an acyclic retinoid, polyprenoic acid, that inhibits hepatocarcinogenesis in laboratory induces differentiation apoptosis cell lines derived from human hepatoma. a randomized, controlled study, we tested whether compound reduced incidence after curative treatment. Methods. prospectively studied 89 who were free disease hepatoma or injection ethanol. randomly assigned to receive either acid (600 mg daily) placebo for 12 months. remnant liver by ultrasonography every three months randomization. The end point study was appearance histologically confirmed new Results. Treatment significantly hepatomas. After median follow-up 38 months, group (27 percent) had as compared 22 (49 percent, P = 0.04). most striking difference groups hepatomas-7 receiving 20 (P=0.04 log-rank test). Cox proportional-hazards analysis demonstrated independent factor, occurrence (adjusted relative risk, 0.31 ; 95 percent confidence interval, 0.12 0.78). Conclusions. Oral prevents original tumor